DK3848027T3 - Octahydro-kondenserede azadecalinglucocorticoidreceptormodulatorer - Google Patents
Octahydro-kondenserede azadecalinglucocorticoidreceptormodulatorer Download PDFInfo
- Publication number
- DK3848027T3 DK3848027T3 DK21158231.7T DK21158231T DK3848027T3 DK 3848027 T3 DK3848027 T3 DK 3848027T3 DK 21158231 T DK21158231 T DK 21158231T DK 3848027 T3 DK3848027 T3 DK 3848027T3
- Authority
- DK
- Denmark
- Prior art keywords
- azadecalinglucocorticoid
- octahydro
- fused
- receptor modulators
- modulators
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361908333P | 2013-11-25 | 2013-11-25 | |
| US201461985035P | 2014-04-28 | 2014-04-28 | |
| EP19177963.6A EP3560493B1 (en) | 2013-11-25 | 2014-11-21 | Octahydro fused azadecalin glucocorticoid receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3848027T3 true DK3848027T3 (da) | 2023-05-01 |
Family
ID=53180165
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14863514.7T DK3074011T3 (da) | 2013-11-25 | 2014-11-21 | Octahydro-kondenserede azadecalin-glucocorticoidreceptormodulatorer |
| DK21158231.7T DK3848027T3 (da) | 2013-11-25 | 2014-11-21 | Octahydro-kondenserede azadecalinglucocorticoidreceptormodulatorer |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14863514.7T DK3074011T3 (da) | 2013-11-25 | 2014-11-21 | Octahydro-kondenserede azadecalin-glucocorticoidreceptormodulatorer |
Country Status (20)
| Country | Link |
|---|---|
| US (7) | US10047082B2 (da) |
| EP (4) | EP3848027B1 (da) |
| JP (5) | JP6516743B2 (da) |
| KR (1) | KR102352737B1 (da) |
| CN (2) | CN109761976B (da) |
| AU (1) | AU2014352915B2 (da) |
| BR (1) | BR112016011826B1 (da) |
| CA (1) | CA2931302C (da) |
| DK (2) | DK3074011T3 (da) |
| ES (3) | ES2869172T3 (da) |
| FI (1) | FI3848027T3 (da) |
| IL (1) | IL245848B (da) |
| MX (1) | MX368167B (da) |
| MY (1) | MY180141A (da) |
| PH (1) | PH12016500968A1 (da) |
| PL (3) | PL3848027T3 (da) |
| PT (2) | PT3074011T (da) |
| RU (1) | RU2674983C1 (da) |
| WO (1) | WO2015077530A1 (da) |
| ZA (1) | ZA201604026B (da) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| PT3074011T (pt) | 2013-11-25 | 2019-09-17 | Corcept Therapeutics Inc | Moduladores de receptores de glicocorticoides de azadecalina fundidas com octa-hidro |
| AU2016243625B2 (en) | 2015-03-30 | 2020-09-10 | Corcept Therapeutics, Inc. | Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency |
| AU2017228329B2 (en) * | 2016-03-01 | 2021-03-11 | Corcept Therapeutics, Inc. | The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors |
| CN106478464B (zh) * | 2016-08-30 | 2018-06-05 | 黄河三角洲京博化工研究院有限公司 | 一种2-氟-6-三氟甲基苯磺酰氯的制备方法 |
| US9943505B2 (en) | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
| US11045482B2 (en) | 2017-03-09 | 2021-06-29 | Corcept Therapeutics, Inc. | Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors |
| UA127409C2 (uk) | 2017-03-31 | 2023-08-16 | Корцепт Терап'Ютікс, Інк. | Модулятори глюкокортикоїдного рецептора для лікування раку шийки матки |
| WO2018209142A2 (en) * | 2017-05-10 | 2018-11-15 | Corcept Therapeutics, Inc. | Octahydro azadecalin formulations |
| WO2018236749A2 (en) | 2017-06-20 | 2018-12-27 | Corcept Therapeutics, Inc. | METHODS OF TREATING NEURO-EPITHELIAL TUMORS USING GLUCOCORTICOID RECEPTOR SELECTIVE MODULATORS |
| AU2019261274B2 (en) * | 2018-04-23 | 2021-10-28 | Corcept Therapeutics, Inc. | Methods of preparing regioselective N-alkyl triazoles |
| TWI811400B (zh) * | 2018-07-20 | 2023-08-11 | 德商歌林達有限公司 | 經進一步取代之***并喹噁啉衍生物 |
| IL263184A (en) | 2018-11-21 | 2020-05-31 | Yarden Yosef | Method of treating cancer and compositions for same |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| CN113194931B (zh) | 2018-12-19 | 2023-11-10 | 科塞普特治疗公司 | 含有瑞拉可兰、杂芳基-酮稠合的氮杂十氢化萘化合物的药物制剂 |
| US11389432B2 (en) | 2018-12-19 | 2022-07-19 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| CA3131263C (en) | 2019-02-22 | 2024-01-02 | Corcept Therapeutics Incorporated | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator |
| CN114929229A (zh) | 2019-12-11 | 2022-08-19 | 科赛普特治疗学股份有限公司 | 用米立可兰治疗抗精神病药导致的体重增加的方法 |
| EP4076470A4 (en) * | 2019-12-21 | 2023-11-22 | Corcept Therapeutics Incorporated | DIFFERENTIAL TREATMENT AND DIAGNOSIS BETWEEN ACTH-DEPENDENT CUSHING SYNDROME AND ACTH-INDEPENDENT CUSHING SYNDROME |
| AU2021296163A1 (en) | 2020-06-22 | 2023-02-02 | Corcept Therapeutics Incorporated | Quaternary indazole glucocorticoid receptor antagonists |
| WO2022134033A1 (en) * | 2020-12-25 | 2022-06-30 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| TW202246260A (zh) * | 2021-02-03 | 2022-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合的氮雜三環類衍生物、其製備方法及其在醫藥上的應用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS322220B1 (da) | 1954-11-30 | 1957-04-11 | ||
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| CA1270488A (en) | 1983-09-26 | 1990-06-19 | John M. Schaus | Pyrazole-ring alkylated pyrazoloquinolines and intermediates |
| GB8828669D0 (en) * | 1988-12-08 | 1989-01-11 | Lilly Industries Ltd | Organic compounds |
| JP3160941B2 (ja) | 1991-06-17 | 2001-04-25 | 東レ株式会社 | カルバゾール誘導体および免疫抑制剤 |
| FR2697252B1 (fr) | 1992-10-28 | 1994-12-09 | Fournier Ind & Sante | Dérivés de 1,2,3,5,6,7,8,8a-octahydro-5,5,8a-triméthyl-(8abeta)-6-isoquinolineamine, leur procédé de préparation et leur utilisation en thérapeutique. |
| US5731322A (en) | 1993-08-06 | 1998-03-24 | Smithkline Beecham S.P.A. | Octahydro-1H-pyrrolo 3,2-g!and 2,3-g!isoquinoline derivatives |
| WO1999045925A1 (en) | 1998-03-10 | 1999-09-16 | Research Triangle Institute | Novel opiate compounds, methods of making and methods of use |
| GB9911053D0 (en) | 1999-05-12 | 1999-07-14 | Pharmacia & Upjohn Spa | 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents |
| WO2003015692A2 (en) | 2001-07-17 | 2003-02-27 | Smithkline Beecham Corporation | Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same |
| EP1408981B1 (en) * | 2001-07-23 | 2008-08-27 | Corcept Therapeutics, Inc. | Methods for preventing antipsychotic-induced weight gain |
| US6679935B2 (en) * | 2001-08-14 | 2004-01-20 | Apex Advanced Technologies, Llc | Lubricant system for use in powdered metals |
| AU2003214879B2 (en) | 2002-01-22 | 2008-02-07 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
| TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
| AU2004270154A1 (en) | 2003-09-03 | 2005-03-17 | Wyeth | Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same |
| KR101135885B1 (ko) | 2004-01-09 | 2012-04-16 | 코어셉트 쎄라퓨틱스, 잉크. | 아자데칼린 글루코코르티코이드 수용체 조절제 |
| JP4931794B2 (ja) | 2004-03-09 | 2012-05-16 | コーセプト セラピューティクス， インコーポレイテッド | 縮合環アザデカリン糖質コルチコイド受容体モジュレーター |
| PL1928840T3 (pl) * | 2005-04-05 | 2012-01-31 | Hoffmann La Roche | 1H-pirazolo-4-karboksyamidy, ich wytwarzanie i ich zastosowanie jako inhibitory dehydrogenazy 11-beta-hydroksysteroidowej |
| US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
| EP2209780B1 (en) | 2007-11-01 | 2014-01-01 | Bristol-Myers Squibb Company | Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and/or nf- kappa b activity and use thereof |
| US8304539B2 (en) * | 2008-02-07 | 2012-11-06 | Bristol-Myers Squibb Company | Fused heteroaryl modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| CA2761255C (en) | 2009-05-12 | 2017-05-09 | Corcept Therapeutics, Inc. | Solid forms and process for preparing (r)-4a-ethoxymethyl-1-(4-fluoro-phenyl)-6-(4-trifluoromethyl-benzenesulfonyl)-4,4a,5,6,7,8-hexahydro-1h,1,2,6-triaza-cyclopenta[b]naphthalene |
| US8710035B2 (en) * | 2010-03-24 | 2014-04-29 | The University Of Chicago | Methods and compositions related to glucocorticoid receptor antagonists and breast cancer |
| SG187909A1 (en) | 2010-08-27 | 2013-03-28 | Corcept Therapeutics Inc | Pyridyl-amine fused azadecalin modulators |
| US8829024B2 (en) | 2011-01-07 | 2014-09-09 | Corcept Therapeutics, Inc. | Combination steroid and glucocorticoid receptor antagonist therapy |
| WO2013130420A1 (en) | 2012-02-27 | 2013-09-06 | Corcept Therapeutics, Inc. | Phenyl heterocycloalkyl glucocorticoid receptor modulators |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| PL3338781T3 (pl) * | 2012-05-25 | 2020-03-31 | Corcept Therapeutics Incorporated | Modulatory receptorów glukokortykoidowych typu azadekaliny skondensowanej z heteroaryloketonem |
| PT3074011T (pt) | 2013-11-25 | 2019-09-17 | Corcept Therapeutics Inc | Moduladores de receptores de glicocorticoides de azadecalina fundidas com octa-hidro |
| US9943505B2 (en) * | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
-
2014
- 2014-11-21 PT PT14863514T patent/PT3074011T/pt unknown
- 2014-11-21 JP JP2016533614A patent/JP6516743B2/ja active Active
- 2014-11-21 BR BR112016011826-0A patent/BR112016011826B1/pt active IP Right Grant
- 2014-11-21 DK DK14863514.7T patent/DK3074011T3/da active
- 2014-11-21 PL PL21158231.7T patent/PL3848027T3/pl unknown
- 2014-11-21 PL PL19177963T patent/PL3560493T3/pl unknown
- 2014-11-21 EP EP21158231.7A patent/EP3848027B1/en active Active
- 2014-11-21 ES ES19177963T patent/ES2869172T3/es active Active
- 2014-11-21 CN CN201910143177.XA patent/CN109761976B/zh active Active
- 2014-11-21 MX MX2016006725A patent/MX368167B/es active IP Right Grant
- 2014-11-21 WO PCT/US2014/066759 patent/WO2015077530A1/en active Application Filing
- 2014-11-21 CA CA2931302A patent/CA2931302C/en active Active
- 2014-11-21 PL PL14863514T patent/PL3074011T3/pl unknown
- 2014-11-21 EP EP19177963.6A patent/EP3560493B1/en active Active
- 2014-11-21 MY MYPI2016000978A patent/MY180141A/en unknown
- 2014-11-21 KR KR1020167017023A patent/KR102352737B1/ko active IP Right Grant
- 2014-11-21 ES ES14863514T patent/ES2743620T3/es active Active
- 2014-11-21 FI FIEP21158231.7T patent/FI3848027T3/fi active
- 2014-11-21 EP EP14863514.7A patent/EP3074011B1/en active Active
- 2014-11-21 AU AU2014352915A patent/AU2014352915B2/en active Active
- 2014-11-21 CN CN201480074087.5A patent/CN106029066B/zh active Active
- 2014-11-21 DK DK21158231.7T patent/DK3848027T3/da active
- 2014-11-21 ES ES21158231T patent/ES2943542T3/es active Active
- 2014-11-21 RU RU2016123449A patent/RU2674983C1/ru active
- 2014-11-21 EP EP23157691.9A patent/EP4219494A1/en active Pending
- 2014-11-21 US US14/549,885 patent/US10047082B2/en active Active
- 2014-11-21 PT PT211582317T patent/PT3848027T/pt unknown
-
2016
- 2016-05-24 PH PH12016500968A patent/PH12016500968A1/en unknown
- 2016-05-25 IL IL245848A patent/IL245848B/en active IP Right Grant
- 2016-06-14 ZA ZA2016/04026A patent/ZA201604026B/en unknown
-
2017
- 2017-10-25 JP JP2017206081A patent/JP2018012734A/ja active Pending
-
2018
- 2018-07-16 US US16/036,001 patent/US20190135805A1/en not_active Abandoned
- 2018-10-16 US US16/161,642 patent/US10323034B2/en active Active
-
2019
- 2019-03-28 JP JP2019063279A patent/JP2019094355A/ja not_active Withdrawn
- 2019-04-12 US US16/382,474 patent/US10787449B2/en active Active
-
2020
- 2020-08-04 US US16/984,914 patent/US11370789B2/en active Active
-
2021
- 2021-01-12 US US17/146,608 patent/US11560379B2/en active Active
- 2021-02-15 JP JP2021021630A patent/JP2021073315A/ja not_active Withdrawn
-
2022
- 2022-11-28 JP JP2022189246A patent/JP2023011052A/ja active Pending
- 2022-12-09 US US18/078,389 patent/US20230167111A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3848027T3 (da) | Octahydro-kondenserede azadecalinglucocorticoidreceptormodulatorer | |
| DK3342773T3 (da) | Syk-hæmmere | |
| DK3613453T3 (da) | Fordamper | |
| ES2635318T7 (es) | Moduladores P2X7 | |
| DK3077047T3 (da) | Aramcholsalte | |
| DK3079743T3 (da) | Anordning | |
| DK3060460T3 (da) | Saddel | |
| DK3027598T3 (da) | Oxoquinazolinyl-butanamidderivater | |
| BR112015022372A2 (pt) | dispositivo | |
| DK2956698T5 (da) | Bindestrimler | |
| DK3052081T3 (da) | Pastil | |
| DK2946640T3 (da) | Langmuir-probe | |
| DK3044389T3 (da) | Vinduespost-tværstykke-konstruktion | |
| DK2999544T3 (da) | Substansfragmenterende indretning | |
| ES2694001T9 (es) | Moduladores de LXR | |
| DK3071227T3 (da) | Fiskevaccine | |
| DE102013106534B8 (de) | Chromatographiepipettenspitze | |
| DE112014001252A5 (de) | Aufbissschiene | |
| DE112013006679T8 (de) | Schlaufenziehervorrichtung | |
| DK2981168T3 (da) | Laminitiskile | |
| DK3086679T3 (da) | Sportssko | |
| ES1078715Y (es) | Mosquitera | |
| FI10659U1 (fi) | Laituri | |
| DE112014005422A5 (de) | Friktionsfalschdrallaggregat | |
| BR112016000501A2 (pt) | Nalador |